Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus /von 2019-04-29 / Int. J. Cancer 2019 10;145(7):1958-1969Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis
/in Cervical Cancer, International Publications, Newcastle Disease Virus /von 2019-04-23 / Saudi J Biol Sci 2020 Jan;27(1):47-52Regression of solid breast tumours in mice by Newcastle disease virus is associated with production of apoptosis related-cytokines
/in Breast Cancer, International Publications, Newcastle Disease Virus /von 2019-04-04 / BMC Cancer 2019 Apr;19(1):315Recent Advances in Cancer Stem Cell-Targeted Immunotherapy
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2019-03-05 / Cancers (Basel) 2019 Mar;11(3)Immunotherapy for Triple-Negative Breast Cancer: Latest Research and Clinical Prospects
/in Breast Cancer, Dendritic Cells, International Publications, Newcastle Disease Virus /von 2019-01-01 / Crit Rev Immunol 2019;39(3):211-221Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials
/in Checkpoint-Inhibitors, International Publications, Newcastle Disease Virus /von 2018-11-14 / Clin Transl Med 2018 Nov;7(1):35Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2018-10-01 / Am J Clin Dermatol 2018 Oct;19(5):657-670The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
/in Breast Cancer, Glioblastoma, International Publications, Malignant Melanoma, Newcastle Disease Virus, Pancreatic Cancer /von 2018-09-26 / Cancers (Basel) 2018 Sep;10(10)Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer
/in International Publications, Newcastle Disease Virus, Ovarian Cancer /von 2018-09-11 / Clin. Cancer Res. 2019 Mar;25(5):1624-1638
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution